No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil

Masayuki Hashiguchi, Hiroyasu Ogata, Akira Maeda, Yuka Hirashima, Shizuka Ishii, Yuko Mori, Toshiaki Amamoto, Toshiya Handa, Norio Otsuka, Shin Irie, Akinori Urae, Ryuji Urae, Ryoji Kimura

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The effects of high-protein food on the bioavailability of both the racemate and individual enantiomers of verapamil were investigated in 12 healthy volunteers using a randomized crossover design. Food had no effect on any parameter of bioavailability for both the racemate and the individual enantiomers of verapamil except time to maximum concentration (t(max)), which was significantly prolonged after food intake. The pharmacokinetics of the enantiomers of norverapamil were not significantly changed by food intake. These results suggests that high-protein food does not alter the pharmacokinetics and bioavailability of either the racemate or the individual enantiomers of verapamil. Therefore, the clinical efficacy of verapamil is not related to food intake, except for a slight prolongation in the time to onset of the pharmacologic effects. The present data can be applied to the high-protein content meal intake.

Original languageEnglish
Pages (from-to)1022-1028
Number of pages7
JournalJournal of Clinical Pharmacology
Volume36
Issue number11
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Verapamil
Biological Availability
Pharmacokinetics
Food
Eating
Proteins
Cross-Over Studies
Meals
Healthy Volunteers

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Hashiguchi, M., Ogata, H., Maeda, A., Hirashima, Y., Ishii, S., Mori, Y., ... Kimura, R. (1996). No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil. Journal of Clinical Pharmacology, 36(11), 1022-1028.

No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil. / Hashiguchi, Masayuki; Ogata, Hiroyasu; Maeda, Akira; Hirashima, Yuka; Ishii, Shizuka; Mori, Yuko; Amamoto, Toshiaki; Handa, Toshiya; Otsuka, Norio; Irie, Shin; Urae, Akinori; Urae, Ryuji; Kimura, Ryoji.

In: Journal of Clinical Pharmacology, Vol. 36, No. 11, 1996, p. 1022-1028.

Research output: Contribution to journalArticle

Hashiguchi, M, Ogata, H, Maeda, A, Hirashima, Y, Ishii, S, Mori, Y, Amamoto, T, Handa, T, Otsuka, N, Irie, S, Urae, A, Urae, R & Kimura, R 1996, 'No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil', Journal of Clinical Pharmacology, vol. 36, no. 11, pp. 1022-1028.
Hashiguchi, Masayuki ; Ogata, Hiroyasu ; Maeda, Akira ; Hirashima, Yuka ; Ishii, Shizuka ; Mori, Yuko ; Amamoto, Toshiaki ; Handa, Toshiya ; Otsuka, Norio ; Irie, Shin ; Urae, Akinori ; Urae, Ryuji ; Kimura, Ryoji. / No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil. In: Journal of Clinical Pharmacology. 1996 ; Vol. 36, No. 11. pp. 1022-1028.
@article{3558cafd1b4c4625a8472ec0021ea34e,
title = "No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil",
abstract = "The effects of high-protein food on the bioavailability of both the racemate and individual enantiomers of verapamil were investigated in 12 healthy volunteers using a randomized crossover design. Food had no effect on any parameter of bioavailability for both the racemate and the individual enantiomers of verapamil except time to maximum concentration (t(max)), which was significantly prolonged after food intake. The pharmacokinetics of the enantiomers of norverapamil were not significantly changed by food intake. These results suggests that high-protein food does not alter the pharmacokinetics and bioavailability of either the racemate or the individual enantiomers of verapamil. Therefore, the clinical efficacy of verapamil is not related to food intake, except for a slight prolongation in the time to onset of the pharmacologic effects. The present data can be applied to the high-protein content meal intake.",
author = "Masayuki Hashiguchi and Hiroyasu Ogata and Akira Maeda and Yuka Hirashima and Shizuka Ishii and Yuko Mori and Toshiaki Amamoto and Toshiya Handa and Norio Otsuka and Shin Irie and Akinori Urae and Ryuji Urae and Ryoji Kimura",
year = "1996",
language = "English",
volume = "36",
pages = "1022--1028",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil

AU - Hashiguchi, Masayuki

AU - Ogata, Hiroyasu

AU - Maeda, Akira

AU - Hirashima, Yuka

AU - Ishii, Shizuka

AU - Mori, Yuko

AU - Amamoto, Toshiaki

AU - Handa, Toshiya

AU - Otsuka, Norio

AU - Irie, Shin

AU - Urae, Akinori

AU - Urae, Ryuji

AU - Kimura, Ryoji

PY - 1996

Y1 - 1996

N2 - The effects of high-protein food on the bioavailability of both the racemate and individual enantiomers of verapamil were investigated in 12 healthy volunteers using a randomized crossover design. Food had no effect on any parameter of bioavailability for both the racemate and the individual enantiomers of verapamil except time to maximum concentration (t(max)), which was significantly prolonged after food intake. The pharmacokinetics of the enantiomers of norverapamil were not significantly changed by food intake. These results suggests that high-protein food does not alter the pharmacokinetics and bioavailability of either the racemate or the individual enantiomers of verapamil. Therefore, the clinical efficacy of verapamil is not related to food intake, except for a slight prolongation in the time to onset of the pharmacologic effects. The present data can be applied to the high-protein content meal intake.

AB - The effects of high-protein food on the bioavailability of both the racemate and individual enantiomers of verapamil were investigated in 12 healthy volunteers using a randomized crossover design. Food had no effect on any parameter of bioavailability for both the racemate and the individual enantiomers of verapamil except time to maximum concentration (t(max)), which was significantly prolonged after food intake. The pharmacokinetics of the enantiomers of norverapamil were not significantly changed by food intake. These results suggests that high-protein food does not alter the pharmacokinetics and bioavailability of either the racemate or the individual enantiomers of verapamil. Therefore, the clinical efficacy of verapamil is not related to food intake, except for a slight prolongation in the time to onset of the pharmacologic effects. The present data can be applied to the high-protein content meal intake.

UR - http://www.scopus.com/inward/record.url?scp=8044226018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8044226018&partnerID=8YFLogxK

M3 - Article

C2 - 8973991

AN - SCOPUS:8044226018

VL - 36

SP - 1022

EP - 1028

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 11

ER -